Regorafenib, a multi-target inhibitor of VEGFR1/2/3, PDGFRβ, and CRAF, has emerged as a notable systemic treatment for HCC patients who had recently received sorafenib treatment, indicating that multi-target inhibition holds tremendous potential in reducing the emergence of resistance [48]. Here, RAF1 is linked to hepatocellular carcinoma.